GB202311170D0 - Antigen binding polypeptides - Google Patents
Antigen binding polypeptidesInfo
- Publication number
- GB202311170D0 GB202311170D0 GBGB2311170.1A GB202311170A GB202311170D0 GB 202311170 D0 GB202311170 D0 GB 202311170D0 GB 202311170 A GB202311170 A GB 202311170A GB 202311170 D0 GB202311170 D0 GB 202311170D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- antigen binding
- binding polypeptides
- polypeptides
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2311170.1A GB202311170D0 (en) | 2023-07-20 | 2023-07-20 | Antigen binding polypeptides |
| PCT/GB2024/051885 WO2025017312A1 (en) | 2023-07-20 | 2024-07-18 | Antigen binding polypeptides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2311170.1A GB202311170D0 (en) | 2023-07-20 | 2023-07-20 | Antigen binding polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202311170D0 true GB202311170D0 (en) | 2023-09-06 |
Family
ID=87851962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2311170.1A Ceased GB202311170D0 (en) | 2023-07-20 | 2023-07-20 | Antigen binding polypeptides |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202311170D0 (en) |
| WO (1) | WO2025017312A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ531208A (en) | 2001-08-31 | 2005-08-26 | Avidex Ltd | Multivalent soluble T cell receptor (TCR) complexes |
| EP3156067A1 (en) * | 2015-10-16 | 2017-04-19 | Max-Delbrück-Centrum Für Molekulare Medizin | High avidity hpv t-cell receptors |
| MX2024005743A (en) * | 2021-11-10 | 2024-05-27 | Tscan Therapeutics Inc | Binding proteins recognizing hpv16 e7 antigen and uses thereof. |
-
2023
- 2023-07-20 GB GBGB2311170.1A patent/GB202311170D0/en not_active Ceased
-
2024
- 2024-07-18 WO PCT/GB2024/051885 patent/WO2025017312A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025017312A1 (en) | 2025-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290268A (en) | Antigen binding proteins specifically binding mage-a | |
| GB202203478D0 (en) | Vh3 binding polypeptides | |
| AU2020243430A1 (en) | Antigen binding proteins | |
| IL285813A (en) | Antigen binding proteins that bind bcma | |
| GB201802338D0 (en) | Antigen binding proteins | |
| GB201919294D0 (en) | Antibodies or binding proteins | |
| IL304745A (en) | Complement c3 antigen binding proteins | |
| IL312652A (en) | Improved antigen binding receptors | |
| IL304317A (en) | Tgf-beta-rii binding proteins | |
| IL325463A (en) | Antigen binding proteins against mageb2 | |
| IL291364A (en) | Antigen binding proteins | |
| GB202113626D0 (en) | FC binding polypeptides | |
| GB202311170D0 (en) | Antigen binding polypeptides | |
| GB202416851D0 (en) | Antigen binding polypeptides | |
| GB202209358D0 (en) | Protein binding assays | |
| GB202315671D0 (en) | Polypeptides | |
| GB202219576D0 (en) | Polypeptides | |
| GB202319661D0 (en) | Antigen binding proteins | |
| HK40105388A (en) | Bma031 antigen binding polypeptides | |
| GB202219294D0 (en) | Antigen binding proteins | |
| GB202316779D0 (en) | Antigen binding protein | |
| GB202101707D0 (en) | Binding polypeptides | |
| GB202302043D0 (en) | Binding proteins | |
| GB202001668D0 (en) | Binding polypeptides | |
| GB202214979D0 (en) | Binding protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |